| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/491205/2011 (24.6.11) |
| Publication Date | 24/06/2011 |
| Content Type | News |
|
The European Medicines Agency (EMA), in June 2011, recommended restricting the use of dexrazoxane to adult patients with advanced or metastatic breast cancer who have already received a certain amount of the anthracyclines doxorubicin and epirubicin to treat their cancer. The Agency’s Committee for Medicinal Products for Human Use (CHMP) also recommended contraindicating the use of this medicine in children. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001288.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
